RELMADA THERAPEUTICS, INC. Common Stock and Additional Paid-In Capital
RELMADA THERAPEUTICS, INC. (RLMD) had Common Stock and Additional Paid-In Capital of $1.01 million as of 2012-04-30, per its 10-KT filed 2014-09-09.
Discontinued › Notes › Equity › Stockholders' Equity Note › Class of Stock Disclosures › Common Stock, Number of Shares, Par Value and Other Disclosure
us-gaap:CommonStocksIncludingAdditionalPaidInCapital · last filed 2014-09-09
- 2012-04-30: Common Stocks, Including Additional Paid in Capital $1.01M.
| Period end | Common Stocks, Including Additional Paid in Capital |
|---|---|
| 2012-04-30 | $1.01M 10-KT · filed 2014-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |